The text discusses the lack of survival benefit with FOLFOX4 compared to LV5FU2 in stage II colon cancer patients. It also mentions a non-significant improvement in disease-free and overall survival with FOLFOX4 in high-risk stage II patients. Additionally, it references a study evaluating the non-inferiority of 3 months versus 6 months of adjuvant chemotherapy in high-risk stage II colon cancer patients.